Publikationen, an denen er mitarbeitet José Ignacio Herrero Santos (13)

2022

  1. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation

    American Journal of Transplantation, Vol. 22, Núm. 6, pp. 1671-1682

  2. De Novo Malignancy after Liver Transplantation: Risk Assessment, Prevention, and Management - Guidelines from the ILTS-SETH Consensus Conference

    Transplantation, Vol. 106, Núm. 1, pp. E30-E45

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2017

  1. Human immunodeficiency virus–infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study

    Liver Transplantation, Vol. 23, Núm. 5, pp. 645-651

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2015

  1. Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients

    Clinical Transplantation, Vol. 29, Núm. 8, pp. 667-677

  2. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain

    Liver Transplantation, Vol. 21, Núm. 8, pp. 1056-1065

  3. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante

    Cirugia Espanola, Vol. 93, Núm. 10, pp. 619-637

2014

  1. "very early" intrahepatic cholangiocarcinoma in cirrhotic patients: Should liver transplantation be reconsidered in these patients?

    American Journal of Transplantation, Vol. 14, Núm. 3, pp. 660-667

  2. IV Reunión de Consenso de la Sociedad Española de Trasplante Hepático 2012. Excepciones al Model for End-stage Liver Disease en la priorización para trasplante hepático

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 2, pp. 83-91

  3. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: A spanish matched cohort multicenter study

    Annals of Surgery, Vol. 259, Núm. 5, pp. 944-952

2012

  1. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation

    Liver Transplantation, Vol. 18, Núm. 1, pp. 45-52

2008

  1. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: Results of a prospective randomized study

    Liver Transplantation, Vol. 14, Núm. 12, pp. 1752-1760